Abstract:
Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease for which great efforts have been made to build up molecular and immunophenotypic subgroups that could accurately indicate prognosis and give clues to therapy. Variable clinical outcomes are seen in response to standard R-CHOP combination therapy. That's why there is a need to identify biomarkers that can identify patients who may benefit from supplemental or alternative therapy and help guide therapeutic decisions. Recently, CD30 was reported as a useful predictor with favorable clinical outcomes. In addition, due to the development of targeted therapies such as an anti-CD30 monoclonal antibody drug conjugate, the identification and prognostic relevance of this biomarker have potential therapeutic impact. CD30 is a cell surface receptor expressed in classical Hodgkin lymphoma (HL), anaplastic large cell lymphoma (ALCL), and many other lymphomas to a variable degree. It has been identified as an important therapeutic target in lymphoma. Its expression in de novo diffuse large-cell B lymphoma defines a new histological entity whose characteristics and prognostic impact are currently being investigated. However, CD30 expression patterns and the clinicopathologic features of CD30-positive DLBCL are not well described thus far. This study aimed to investigate the positive expression rate and prognostic impact of CD30 in de novo DLBCLs and try to find the correlated influences.
|